Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Plasma cell 1Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Large B-Cell, Diffuse 21Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hodgkin Disease 15Lymphoma, T-Cell, Cutaneous 13Leukemia, Lymphocytic, Chronic, B-Cell 12Mycosis Fungoides 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Acute 11Burkitt Lymphoma 11Sezary Syndrome 9Lymphoma, Large-Cell, Anaplastic 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, T-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Immunoblastic Lymphadenopathy 7Blast Crisis 7Myeloproliferative Disorders 6Lymphoma, Extranodal NK-T-Cell 6Lymphoma, B-Cell 6Leukemia 6Waldenstrom Macroglobulinemia 5Recurrence 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Myeloid, Accelerated Phase 5Congenital Abnormalities 5

Interventions

pembrolizumab 14Nivolumab 9Specimen Handling 4Magnetic Resonance Spectroscopy 4fludarabine 3atezolizumab 3Ipilimumab 3Drug Therapy 3Cyclophosphamide 3epacadostat 2entrectinib 2durvalumab 2X-Rays 2Sirolimus 2Radiotherapy 2Radiation 2Methods 2Interleukin-2 2Injections 2CTLA-4 Antigen 2Blood Specimen Collection 2Biopsy 2zimberelimab 1vocimagene amiretrorepvec 1varlilumab 1utomilumab 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Vorinostat × Lymphoid × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡